Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CervoMed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CervoMed's regulatory disclosures and financial reporting.
CervoMed Inc. (CRVO) reported an insider transaction on a Form 4. A director and 10% owner purchased 5,553 shares of common stock in open‑market transactions on 11/12/2025 at a price of $7.35 per share. Following the purchase, the reporting person beneficially owned 1,467,131 shares. The filing notes these shares are held jointly with the reporting person’s spouse, Dr. John Alam, M.D., the company’s President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported an insider stock purchase by its CFO, GC & Secretary, William R. Elder. On 11/12/2025, Elder bought 3,500 shares of common stock in open‑market transactions at $7.44 per share (Transaction Code: P). Following the transaction, his direct holdings total 9,000 shares. The filing was submitted by one reporting person.
CervoMed Inc. (CRVO) insider purchase: The CEO & President, who is also a Director and 10% Owner, bought 5,553 shares of common stock at $7.35 on 11/12/2025 in open‑market transactions. Following the purchase, he beneficially owned 1,467,131 shares, reported as directly held. The filing notes these shares are held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, PharmD, a member of the Board of Directors.
CervoMed Inc. furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The disclosure is provided under Item 2.02 and is being furnished, not deemed “filed” for purposes of Section 18 of the Exchange Act. CervoMed’s common stock trades on the NASDAQ Capital Market under the symbol CRVO.
CervoMed Inc. filed a Form S-8 to register 800,000 shares of common stock for issuance under its 2025 Equity Incentive Plan, and 129,000 shares of common stock issuable upon exercise of previously announced non-qualified stock option inducement awards granted on June 9, 2025 and October 6, 2025 in accordance with Nasdaq Listing Rule 5635(c)(4).
The filing incorporates CervoMed’s recent 10-Qs for the quarters ended March 31, June 30, and September 30, 2025, and multiple 8-Ks filed in 2025. It also summarizes the company’s Delaware-law indemnification framework for directors and officers and lists exhibits including the legal opinion, auditor consent, and plan documents.
CervoMed Inc. filed its Q3 2025 10‑Q, reporting a net loss of $7,726,639 on grant revenue of $322,569. Operating expenses were $8,366,768, including $6,040,442 for research and development and $2,326,326 for general and administrative costs. Other income totaled $317,560.
The company ended the quarter with $27.3 million in cash, cash equivalents, and marketable securities and stated that these resources are insufficient to fund operations for at least twelve months, creating substantial doubt about its ability to continue as a going concern. For the first nine months of 2025, CervoMed reported a net loss of $18,879,077 and used $16,874,264 in operating cash flow, partially offset by $4,588,687 of net proceeds from selling 550,000 shares under its at‑the‑market program. As of November 5, 2025, common shares outstanding were 9,252,719. The NIA grant has delivered $19.5 million to date, with approximately $1.6 million remaining under current awards.
CervoMed (CRVO) furnished an 8-K stating it received written feedback from the U.S. Food and Drug Administration aligning on key aspects of its proposed Phase 3 clinical trial of neflamapimod for patients with dementia with Lewy bodies. The company disclosed this via a press release furnished under Regulation FD.
Selected sections of the press release—covering the initial overview, “Phase 3 Trial Design and Regulatory Alignment,” and part of “Advancing Towards Registration”—are incorporated by reference under Other Events. The 8-K notes the press release is furnished, not filed, under the Exchange Act.
CervoMed Inc. appointed David Quigley to its Board of Directors. The Board expanded from seven to eight members, and Quigley will serve until the next annual meeting. He brings over 25 years at McKinsey, including roles leading Private Capital and Life Sciences practices.
In connection with his appointment, Quigley received a stock option for 16,200 shares at an exercise price of $7.02, vesting in 36 equal monthly installments beginning October 31, 2025, under the 2025 Equity Incentive Plan. He will also receive standard non-employee director cash and equity compensation and entered into the company’s standard director and officer indemnification agreement. Quigley will not serve on any standing committees.
CervoMed Inc. furnished a Regulation FD update, noting that an investor presentation is available on its website under “Investors – Events and Presentations.” Company representatives may use the materials periodically in meetings and conferences.
The information is being furnished, not filed, and may be updated at management’s discretion as warranted by law. The filing also lists Exhibit 104, the cover page interactive data file embedded in Inline XBRL.
CervoMed Inc. furnished an update on its lead program by sharing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies. The company issued a press release and also posted a detailed investor presentation on its website under “Investors – Events and Presentations,” which covers business, clinical studies, development plans and financial position along with the new trial results. This information is provided as a Regulation FD disclosure and is treated as “furnished,” not “filed,” and is also incorporated by reference into an other-events section of this report.